Abstract
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Altretamine / adverse effects
-
Altretamine / therapeutic use*
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / secondary
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Male
-
Middle Aged
-
Survival Rate
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Altretamine